Vanda Pharmaceuticals' NEREUS™ Gains FDA Approval for Motion Sickness Prevention
Vanda Pharmaceuticals received FDA approval for NEREUS (tradipitant), the first new drug in over 40 years for preventing motion sickness-induced vomiting, supported by robust clinical trial data showing significant efficacy and safety, marking a major advancement in treatment options for this condition affecting millions.